Morvus Technology

United Kingdom
Caerfyrddin, Carmarthenshire, United Kingdom, SA32 8HZ

Company profile

Morvus Technology company profile

Morvus Technology Ltd., a pharmaceutical company, engages in the discovery, development, and commercialization of drugs and technologies in the oncology field. Its clinical candidates include MTL-005, a therapy for cancers treated with conventional radiotherapy; MTL-007, a novel anti-cancer prodrug; and MTL-003, an anti-angiogenic cancer therapy. The company's research portfolio comprises MorTar platform technology that identifies new proteins and genes that share the ability to inhibit apoptosis; HAI-X, an anti-angiogenic treatment for prostate cancer; and MorGen, a novel prodrug-activating system. The company also engages in the development of anti-cancer treatments using genetic modification techniques. In addition, it offers MorAnt, an anti-parasitic drug; and MorRid, a rodenticide. Morvus Technology Ltd. was founded in 2004 and is based in Carmarthen, the United Kingdom.

Business identity

Contact email
[email protected]
Phone number
44 15 5866 8111
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2004-01-01, Year

Headquarters

Postal code
SA32 8HZ
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
1
Total equity funding
$3.3M
Last funding
Series A / $3.3M / 2010-02-11
Last equity funding
Series A / $3.3M
Investors
1
Founders
1

Founders and investors

Founders

Philip Burke

Investors

Fusion IP